GleamWall
中文EN

COLL COLLEGIUM PHARMACEUTICAL, INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1267565 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY7.7%
TTM net income YoY-34.7%
TTM EPS YoY-37.9%
Revenue 3-yr CAGR14.2%
Net income 3-yr CAGR61.8%

Margins

Gross margin59.0%
Operating margin15.2%
Net margin4.7%
FCF margin41.3%
EBITDA margin15.7%

Returns

ROE13.4%
ROA2.1%
ROIC (approx.)81.3%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets85.9%
Debt / equity0.00x
Current ratio1.01x
Interest coverage1.62x

Cash quality & payout

Operating cash flow / net income8.86x
Accruals ratio-16.2%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q42025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q42024-12-31
Income statement
Revenue$216.34M$199.88M$193.52M$205.45M$209.36M$188.00M$177.76M$181.95M
Cost of revenue$90.92M$89.59M$76.27M$77.07M$80.19M$79.62M$80.43M$83.66M
Gross profit$125.42M$110.29M$117.25M$128.38M$129.17M$108.38M$97.32M$98.29M
SG&A expense$99.59M$106.59M$86.35M$67.64M$67.10M$73.64M$76.42M$63.09M
Operating income$28.72M$3.70M$30.90M$60.76M$62.09M$35.10M$21.69M$38.11M
Interest expense$21.94M$19.52M$15.86M$19.29M$21.77M$20.46M$20.79M$22.65M
Pretax income$7.91M-$13.53M$18.74M$29.04M$43.44M$17.02M$3.12M$17.27M
Income tax-$13.85M$1.52M$4.24M$12.07M$11.93M$5.04M$705,000$4.73M
Net income$21.76M-$15.05M$14.50M$16.96M$31.51M$11.98M$2.42M$12.54M
EBITDA$29.21M$5.51M$31.36M$61.68M$63.12M$36.24M$22.78M$39.15M
EPS (basic)0.69-0.460.450.541.000.380.080.39
EPS (diluted)0.60-0.460.400.460.840.340.070.36
Weighted avg. shares (diluted)39.11M32.46M40.07M40.08M39.44M39.08M32.84M40.11M
Balance sheet
Cash & equivalents$144.80M$129.47M$268.65M$231.25M$150.10M$117.35M$96.19M$96.61M
Short-term investments$0$0$153.10M$155.43M$135.77M$104.81M$101.58M$92.20M
Receivables$310.79M$285.10M$228.76M$211.33M$233.95M$213.02M$228.71M$228.54M
Inventory$88.20M$113.27M$42.74M$40.91M$38.05M$38.15M$37.22M$35.56M
Current assets$611.75M$608.01M$745.67M$691.41M$613.87M$549.21M$527.55M$482.26M
PP&E, net$10.88M$10.65M$11.66M$12.01M$12.25M$12.90M$13.85M$14.33M
Goodwill$193.88M$190.18M$145.93M$145.93M$145.93M$147.94M$150.76M$162.33M
Intangibles$1.13B$1.19B$614.04M$669.51M$724.98M$780.46M$835.93M$891.40M
Total assets$2.10B$2.14B$1.65B$1.66B$1.61B$1.59B$1.63B$1.66B
Current liabilities$603.09M$589.86M$434.97M$440.03M$452.93M$464.61M$486.71M$509.51M
Total liabilities$1.80B$1.82B$1.34B$1.36B$1.33B$1.36B$1.40B$1.43B
Shareholders' equity$296.44M$311.91M$312.42M$301.68M$274.81M$232.21M$234.43M$228.84M
Shares outstanding31.07M32.50M32.41M31.71M31.60M31.55M32.13M31.44M
Cash flow statement
Operating cash flow$86.54M$71.32M$57.11M$123.05M$78.44M$72.44M$55.40M$84.64M
Capital expenditure$277,000$496,000$270,000$689,000$188,000$65,000$798,000$570,000
Free cash flow$86.26M$70.83M$56.84M$122.36M$78.25M$72.37M$54.60M$84.07M
Investing cash flow-$277,000-$502.59M$1.63M-$20.07M-$30.87M-$2.92M-$9.68M-$11.76M
Financing cash flow-$70.93M$292.09M-$21.34M-$21.82M-$14.82M-$48.37M-$25.24M-$41.28M
Depreciation & amortization$491,000$1.81M$463,000$923,000$1.03M$1.14M$1.09M$1.04M
Stock-based compensation$12.45M$14.48M$10.88M$9.75M$9.81M$10.82M$11.52M$7.60M
Share buybacks—$0—$0$0$25.10M—$25.02M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.